Sherly Mosessian, PhD, SOFIE’s Chief Scientific Officer, has been recognized by the organization Women We Admire, as one of the Top 25 Women Chief Scientific Officers in 2025. The list of honorees includes female scientific leaders across healthcare, technology, and sustainability. Dr. Mosessian is distinguished for being “strategic-minded, results-focused and embracing a culture of collaboration and teamwork”.

Dr. Mosessian is praised for her creative leadership in biomedical research and technology in previous roles, including development of a translational pathway to effectively move PET imaging agents from the lab to clinical applications at UCLA’s Department of Molecular and Medical Pharmacology.

At SOFIE since 2022, Dr. Mosessian leads clinical development efforts for diagnostic use of SOFIE’s own intellectual property, [18F]FAPI-74. Following a successful End of Phase 2 meeting with the FDA last month, SOFIE is preparing to launch two Phase 3 clinical trials in gastroesophageal cancers and PDAC with [18F]FAPI-74.

Congrats to Dr. Mosessian!